<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2144">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857310</url>
  </required_header>
  <id_info>
    <org_study_id>FAZST</org_study_id>
    <nct_id>NCT01857310</nct_id>
  </id_info>
  <brief_title>Folic Acid and Zinc Supplementation Trial (FAZST)</brief_title>
  <acronym>FAZST</acronym>
  <official_title>Folic Acid and Zinc Supplementation Trial: A Multi-center, Double-blind, Block-randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this trial is to determine if an intervention comprising folic acid&#xD;
      and zinc dietary supplementation improves semen quality and indirectly fertility outcomes&#xD;
      (i.e., live birth rate) among couples trying to conceive and seeking assisted reproduction.&#xD;
      The following study objectives underlie successful attainment of the overarching research&#xD;
      goal:&#xD;
&#xD;
        1. To estimate the effect of folic acid and zinc dietary supplementation on semen quality&#xD;
           parameters, including but not limited to concentration, motility, morphology, and sperm&#xD;
           DNA integrity, relative to the placebo group.&#xD;
&#xD;
        2. To estimate the effect of folic acid and zinc dietary supplementation on fertility&#xD;
           treatment outcomes [fertilization, embryo quality, implantation/human Chorionic&#xD;
           Gonadotropin (hCG) confirmed pregnancy, clinical pregnancy, live birth], relative to the&#xD;
           placebo group.&#xD;
&#xD;
        3. To estimate the association between semen quality parameters, sperm DNA integrity and&#xD;
           fertility treatment outcomes (fertilization, embryo quality, clinical pregnancy, live&#xD;
           birth) and to identify the best combination of semen quality parameters for prediction&#xD;
           of clinical pregnancy and live birth.&#xD;
&#xD;
        4. To estimate the effect of folic acid and zinc dietary supplementation on fertilization&#xD;
           rates among couples undergoing assisted reproductive technology procedures, relative to&#xD;
           the placebo group.&#xD;
&#xD;
        5. To estimate the effect of folic acid and zinc dietary supplementation on embryonic&#xD;
           quality among couples undergoing assisted reproductive technology procedures, relative&#xD;
           to the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two micronutrients fundamental to the process of spermatogenesis, folic acid (folate) and&#xD;
      zinc, are of particular interest for fertility as they are of low cost and wide availability.&#xD;
      Though the evidence has been inconsistent, small randomized trials and observational studies&#xD;
      show that folate and zinc have biologically plausible effects on spermatogenesis and improved&#xD;
      semen parameters. These results support the potential benefits of folate on spermatogenesis&#xD;
      and suggest that dietary supplementation with folate and zinc may help maintain and improve&#xD;
      semen quality, and perhaps, fertility rates.&#xD;
&#xD;
      The Epidemiology Branch of the Eunice Kennedy Shriver National Institute of Child Health and&#xD;
      Human Development intends to conduct a multi-site double-blind, randomized controlled&#xD;
      clinical trial to evaluate the effect of folic acid and zinc dietary supplementation on semen&#xD;
      quality and conception rates among male partners of couples seeking assisted reproduction.&#xD;
      Randomization will be stratified (with random sequences of block sizes) by site and assisted&#xD;
      reproduction technique (IVF, non-IVF receiving fertility treatment at a study site, and&#xD;
      non-IVF receiving fertility treatment at a nonstudy site) to ensure that balance between the&#xD;
      treatment groups is maintained within site and within fertility treatment type over the&#xD;
      enrollment period.&#xD;
&#xD;
      The study is designed with a sample size of 2,400 randomized participants based on obtaining&#xD;
      adequate power to detect meaningful differences in the live birth rate between cohorts. Since&#xD;
      the comparison of sperm parameters are differences between continuous assay measurements,&#xD;
      this sample size will be more than sufficient for the primary sperm parameter comparisons.&#xD;
      Additionally, calculations were done to demonstrate adequate statistical power when&#xD;
      stratified analysis is to be performed (i.e., sample size distributions among the strata and&#xD;
      their corresponding live birth RRs detected at 80% statistical power, with an alpha level of&#xD;
      0.05 and a total sample size of 2400 couples divided among the folic acid/zinc and placebo&#xD;
      arms of the trial).&#xD;
&#xD;
      Data collection will include screening male and female partners for eligibility,&#xD;
      administering baseline questionnaires, and collecting biospecimens in both partners of the&#xD;
      couple, body measurements for both partners, daily journal reporting for male partners,&#xD;
      medical record abstraction related to required treatment and outcome data, and semen quality&#xD;
      of four samples collected at baseline, two, four, and six months following study enrollment.&#xD;
      A data coordinating center (DCC) will support the trial.&#xD;
&#xD;
      The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the&#xD;
      two cohorts based on the randomized assignment, both overall and by treatment strata (IVF,&#xD;
      non-IVF receiving fertility treatment at a study site, and non-IVF receiving fertility&#xD;
      treatment at a nonstudy site).This approach will be applied to the two primary endpoints&#xD;
      (semen parameters and live birth rate) as well as designated secondary endpoints (number of&#xD;
      follicles, number and proportion of oocytes fertilized).&#xD;
&#xD;
      The DCC will perform periodic safety analyses and present interim reports to the Data and&#xD;
      Safety Monitoring Board (DSMB) as requested, during the recruitment phases of the trial. It&#xD;
      is anticipated that safety analyses will be performed every 6-12 months. The final analysis&#xD;
      will be performed upon completion of data collection and editing in the follow-up and&#xD;
      close-out phase of the trial. Also one full formal interim analysis is planned and the power&#xD;
      calculations with considerations for the choice of optimal time for the analysis have been&#xD;
      conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth</measure>
    <time_frame>At delivery</time_frame>
    <description>Based on hospital delivery records</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Motility</measure>
    <time_frame>6 months</time_frame>
    <description>% motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm Morphology</measure>
    <time_frame>6 months</time_frame>
    <description>% normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA Fragmentation Index</measure>
    <time_frame>6 months</time_frame>
    <description>Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Motile Sperm Count</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation)</measure>
    <time_frame>For IVF, 12 days post embryo transfer for day 5 embryo transfers, and 14 days post embryo transfer for day 3 embryo transfers; for couples undergoing OI/IUI, after self-report of positive pregnancy test</time_frame>
    <description>A quantitative hCG evaluation in serum &gt; 5 milli-international units per milliliter (mIU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Intrauterine Pregnancy</measure>
    <time_frame>approximately 6.5 weeks gestation</time_frame>
    <description>Visualized gestational sac in the uterus on ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic Pregnancy</measure>
    <time_frame>approximately 6.5 weeks gestation</time_frame>
    <description>Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Pregnancy Loss</measure>
    <time_frame>hcG-detected pregnancy until 20 weeks of pregnancy</time_frame>
    <description>hCG pregnancy loss will be defined as a serum hCG &gt; 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia or Gestational Hypertension</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Diabetes</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for Gestational Age</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>Delivery</time_frame>
    <description>Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Mortality</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Neonatal Complications</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural Malformations</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Maternal Morbidity</measure>
    <time_frame>Delivery</time_frame>
    <description>Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate Per Cycle, %</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Good Quality Embryos on Day 5 Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Good Quality Embryos on Day 5 Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Embryos Transferred Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Embryos Cryopreserved Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm Penetration Per Cycle, %</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cells on Day 3 Per Embryo Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cells on Day 3 Per Embryo Per Cycle, Categorical</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Number of cells per embryo among women in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cells on Day 5 Per Embryo Per Cycle, Categorical</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Morphology on Day 3 Per Cycle, Categorical</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation.&#xD;
Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Morphology on Day 5 Per Cycle, Categorical</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Method of Fertilization Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Embryos Transferred Per Cycle, Categorical</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chromosomal Complement of Embryo Per Cycle</measure>
    <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
    <description>Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al.&#xD;
Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reproductive Hormones and Other Measured Biomarkers</measure>
    <time_frame>4 or 6 months</time_frame>
    <description>Urinary, serum, and salivary concentrations of reproductive hormones, particularly androgens, proteomic analysis of human sperm and cardiometabolic risk factors and markers of oxidative stress, as well as measures of trace elements in toenails (collected at month 4 clinic visit). Biospecimens have been collected but laboratory analysis still needs to be done to be able to evaluate these endpoints.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2370</enrollment>
  <condition>Pregnancy</condition>
  <condition>Live Birth</condition>
  <condition>Spontaneous Abortion</condition>
  <arm_group>
    <arm_group_label>Folic acid and zinc supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, taken orally daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>5 mg folic acid and 30 mg elemental zinc</intervention_name>
    <arm_group_label>Folic acid and zinc supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Couples Inclusion Criteria:&#xD;
&#xD;
          1. Heterosexual couples in a committed relationship with a female partner aged 18-45&#xD;
             years and male partner aged 18 years and older attempting to conceive and seeking&#xD;
             assisted reproduction at participating fertility clinics.&#xD;
&#xD;
          2. Couples actively trying to conceive.&#xD;
&#xD;
          3. Couples who are planning ovulation induction (OI), natural fertility optimization&#xD;
             methods, or intrauterine insemination (IUI) should be willing to be on the study&#xD;
             dietary supplement for at least 3 weeks before starting the next assisted reproduction&#xD;
             cycle.Women with regular periods may initiate their fertility therapy at the start of&#xD;
             the woman's menstrual cycle following randomization if randomization occurred within&#xD;
             the first 10 days of the cycle, but must wait one menstrual cycle if the visit&#xD;
             occurred after day 10 of the cycle). For women with irregular periods or amenorrhea,&#xD;
             the male must be on the study supplement for 3 weeks prior to initiation of any&#xD;
             ovulation induction medication (e.g., clomid, letrozole, gonadotropins).&#xD;
&#xD;
        Couples Exclusion Criteria:&#xD;
&#xD;
          1. Female partner unwilling to participate (e.g., no abstraction of her assisted&#xD;
             fertility treatment record or unwilling to complete baseline visit).&#xD;
&#xD;
          2. Couples using donor, cryopreserved sperm, or sperm obtained via microsurgical or&#xD;
             percutaneous epididymal sperm aspiration.&#xD;
&#xD;
          3. Couples attempting to conceive with a gestational carrier (surrogate).&#xD;
&#xD;
          4. Positive urine pregnancy test at screening.&#xD;
&#xD;
        Male Inclusion Criteria:&#xD;
&#xD;
          1. Willing to provide semen samples according to the proposed schedule at baseline, 2, 4,&#xD;
             and 6 months of follow-up.&#xD;
&#xD;
          2. Able to complete regular study questionnaires and daily journals aimed at capturing&#xD;
             ejaculation, sexual intercourse and lifestyle factors considered to affect male&#xD;
             fecundity (e.g., cigarette smoking, fever, high temperature environment and other&#xD;
             environmental exposures) and other data collection instruments (e.g., physical&#xD;
             activity, food frequency questionnaire, stress).&#xD;
&#xD;
        Male Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years.&#xD;
&#xD;
          2. Unwilling to abstain from use of non-study approved dietary supplements or medications&#xD;
             containing folic acid or oral preparations containing zinc throughout the study.&#xD;
&#xD;
          3. Unwilling to abstain from use of testosterone supplementation throughout the study.&#xD;
&#xD;
          4. Diagnosis of Vitamin B12 deficiency or pernicious anemia.&#xD;
&#xD;
          5. Consuming a vegan diet.&#xD;
&#xD;
          6. A known genetic cause of male factor subfertility, including chromosomal disorders&#xD;
             related to subfertility (e.g., Y chromosome deletions).&#xD;
&#xD;
          7. Males currently using and unwilling (or unable) to discontinue the following drugs&#xD;
             known to interact with folic acid or interfere with the biosynthesis of folic acid&#xD;
             will be excluded.&#xD;
&#xD;
               1. Dihydrofolate reductase inhibitors: Trimethoprim, Triamterene, Bactrim, Iclaprim&#xD;
&#xD;
               2. Sulfonamides: Hydrochlorothiazide (HCTZ), Metolazone, Indapamide, Lasix, Bumex,&#xD;
                  Torsemide, Chlorthalidone, Acetazolamide, Mefruside, Xipamide&#xD;
&#xD;
               3. Sulfonylureas: Glipizide, Glyburide&#xD;
&#xD;
               4. Cox-2 inhibitors: Celecoxib&#xD;
&#xD;
               5. Others: Valproic acid, Probenecid, Sulfasalazine, Sumatriptan, Mafenide,&#xD;
                  Ethoxzolamide, Sulfiram, Zonisamide, Dorzolamide (optic), Dichlorphenamide,&#xD;
                  Fluorouracil, Capecitabine, Methotrexate&#xD;
&#xD;
          8. History of organ transplantation.&#xD;
&#xD;
          9. Physician diagnosed:&#xD;
&#xD;
               1. Current poorly controlled chronic diseases such as heart disease, diabetes&#xD;
                  mellitus, hypertension, cancer, inflammatory diseases, autoimmune, thyroid&#xD;
                  disease, endocrine dysfunction, liver disease, kidney disease, or HIV/AIDS or&#xD;
                  other immune-insufficient related illnesses.&#xD;
&#xD;
               2. Crohn's disease, celiac disease, ulcerative colitis, gastric bypass surgery, lap&#xD;
                  band surgery or history of intestinal surgery to remove a portion of small bowel.&#xD;
                  History of diseases/symptoms that require folic acid dietary supplementation,&#xD;
                  such as megaloblastic anemia, homocystinemia, and homocystinuria.&#xD;
&#xD;
               3. History of alcohol dependency disorder and/or other drug/substance dependency in&#xD;
                  the past 180 days.&#xD;
&#xD;
               4. History of psychoses or other mental conditions that would result in cognitive&#xD;
                  impairment and inability to participate in any part of this study including the&#xD;
                  informed consent process, as diagnosed by a physician within the past year.&#xD;
&#xD;
         10. History of vasectomy without reversal, obstructive azoospermia such as Congenital&#xD;
             Bilateral Aplasia of Vas Deferens (CBAVD), or ejaculatory duct obstruction.&#xD;
&#xD;
         11. Known allergy to folic acid or zinc dietary supplements.&#xD;
&#xD;
        Female Exclusion Criteria:&#xD;
&#xD;
        Age &lt;18 or &gt;45 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique F. Schisterman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunni L. Mumford, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Matthew Peterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jared C. Robins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ginny L. Ryan, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley J. Van Voorhis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nichd.nih.gov/about/org/diphr/officebranch/eb/folic-acid-zinc</url>
    <description>The FAZST trial home page</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <results_first_submitted>August 30, 2020</results_first_submitted>
  <results_first_submitted_qc>November 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Folic Acid</keyword>
  <keyword>Zinc</keyword>
  <keyword>Semen</keyword>
  <keyword>In vitro fertilization</keyword>
  <keyword>Assisted reproductive technology</keyword>
  <keyword>Ovulation induction</keyword>
  <keyword>Intrauterine insemination</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Live Birth</keyword>
  <keyword>Abortion, spontaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT01857310/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Only the male partners in couples attempting to conceive were enrolled and assigned to treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Folic Acid and Zinc Supplementation</title>
          <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Analysis: Live Birth</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1185">Male partner</participants>
                <participants group_id="P2" count="1185">Male partner</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1185">Chart abstraction of whether live birth occurred</participants>
                <participants group_id="P2" count="1185">Chart abstraction of whether live birth occurred</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Secondary Analysis: Semen Quality at 6m</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1185">Male partner</participants>
                <participants group_id="P2" count="1185">Male partner</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="870">Completed 6-month study visit</participants>
                <participants group_id="P2" count="903">Completed 6-month study visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only male partners randomized to each folic acid/zinc (n = 1185) and placebo (n = 1185) arms</population>
      <group_list>
        <group group_id="B1">
          <title>Folic Acid and Zinc Supplementation</title>
          <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2370"/>
            <count group_id="B2" value="2370"/>
            <count group_id="B3" value="4740"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Male-female couples</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1185"/>
            <count group_id="B2" value="1185"/>
            <count group_id="B3" value="2370"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Male partner age, continuous</description>
          <population>Male partners</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="5.7"/>
                    <measurement group_id="B2" value="32.7" spread="6.0"/>
                    <measurement group_id="B3" value="32.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Female partner age, continuous</description>
          <population>Female partners</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="5.0"/>
                    <measurement group_id="B2" value="30.8" spread="5.2"/>
                    <measurement group_id="B3" value="30.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="2370"/>
                <count group_id="B2" value="2370"/>
                <count group_id="B3" value="4740"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1185"/>
                    <measurement group_id="B2" value="1185"/>
                    <measurement group_id="B3" value="2370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1185"/>
                    <measurement group_id="B2" value="1185"/>
                    <measurement group_id="B3" value="2370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Male partner race/ethnicity, customized</description>
          <population>Male partners</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Non-Hispanic white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="974"/>
                    <measurement group_id="B2" value="962"/>
                    <measurement group_id="B3" value="1936"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other racial/ethnic groups</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not wish to provide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Female partner race/ethnicity, customized</description>
          <population>Female partners</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Non-Hispanic white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="962"/>
                    <measurement group_id="B3" value="1956"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other racial/ethnic groups</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not wish to provide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <description>Male partner body mass index</description>
          <population>Male partners</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="6.7"/>
                    <measurement group_id="B2" value="29.6" spread="6.7"/>
                    <measurement group_id="B3" value="29.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <description>Male partner systolic blood pressure</description>
          <population>Male partners</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.8" spread="12.8"/>
                    <measurement group_id="B2" value="126.5" spread="13.9"/>
                    <measurement group_id="B3" value="126.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <description>Male partner diastolic blood pressure</description>
          <population>Male partners</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" spread="10.8"/>
                    <measurement group_id="B2" value="78.0" spread="10.9"/>
                    <measurement group_id="B3" value="78.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <description>Male partner education</description>
          <population>Male partners</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High school or less</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="814"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bachelor's degree</title>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="389"/>
                    <measurement group_id="B3" value="724"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Master's degree or higher</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not wish to provide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment status</title>
          <description>Male partner employment status</description>
          <population>Male partners: 89 participants in the FA/Zn arm and 90 participants in the placebo arm did not provide this information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1096"/>
                <count group_id="B2" value="1095"/>
                <count group_id="B3" value="2191"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not employed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Employed part-time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Employed full-time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="802"/>
                    <measurement group_id="B2" value="798"/>
                    <measurement group_id="B3" value="1600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Full-time student</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <population>Measure assessed among each of 2370 male-female couples (n=1185 active and 1185 placebo)</population>
          <units>Male-female couples</units>
          <param>Count of Units</param>
          <units_analyzed>Male-female couples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Married/living with partner</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1180"/>
                    <measurement group_id="B2" value="1179"/>
                    <measurement group_id="B3" value="2359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Single/other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not wish to provide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Annual household income</title>
          <population>Measure assessed among each of 2370 male-female couples (n=1185 active and 1185 placebo)</population>
          <units>Male-female couples</units>
          <param>Count of Units</param>
          <units_analyzed>Male-female couples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;$40,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>$40,000-$74,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="878"/>
                  </measurement_list>
                </category>
                <category>
                  <title>$75,000-$99,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="493"/>
                  </measurement_list>
                </category>
                <category>
                  <title>$100,000 and greater</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not wish to provide</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking multivitamin within past 3 mo</title>
          <description>Male partner taking multivitamin within past 3 mo</description>
          <population>Male partners: 434 participants in the FA/Zn arm and 433 participants in the placebo arm did not provide this information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="751"/>
                <count group_id="B2" value="752"/>
                <count group_id="B3" value="1503"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="582"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="468"/>
                    <measurement group_id="B3" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Male factor infertility diagnosis</title>
          <description>Baseline male factor infertility diagnosis includes low sperm count, low sperm motility, abnormal morphology, poor DNA fragmentation, testicular failure, and other.</description>
          <population>Male partners: 427 participants in the FA/Zn arm and 426 participants in the placebo arm did not provide this information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="758"/>
                <count group_id="B2" value="759"/>
                <count group_id="B3" value="1517"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="598"/>
                    <measurement group_id="B2" value="594"/>
                    <measurement group_id="B3" value="1192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Male health insurance</title>
          <population>Male partners: 12 participants in the FA/Zn arm and 14 participants in the placebo arm did not provide this information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1173"/>
                <count group_id="B2" value="1171"/>
                <count group_id="B3" value="2344"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1108"/>
                    <measurement group_id="B2" value="1117"/>
                    <measurement group_id="B3" value="2225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Male infertility insurance</title>
          <population>Male partners: 79 participants in the FA/Zn arm and 69 participants in the placebo arm did not provide this information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1106"/>
                <count group_id="B2" value="1116"/>
                <count group_id="B3" value="2222"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1185"/>
                <count group_id="B2" value="1185"/>
                <count group_id="B3" value="2370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="563"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="495"/>
                    <measurement group_id="B3" value="988"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Do not know</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time trying to conceive</title>
          <population>Measure assessed among each of 2370 male-female couples (n=1185 active and 1185 placebo): 83 couples in the FA/Zn arm and 80 couples in the placebo arm did not provide this information.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Male-female couples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1102"/>
                <count group_id="B2" value="1105"/>
                <count group_id="B3" value="2207"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Male-female couples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1102"/>
                <count group_id="B2" value="1105"/>
                <count group_id="B3" value="2207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" lower_limit="12" upper_limit="36"/>
                    <measurement group_id="B2" value="18" lower_limit="12" upper_limit="36"/>
                    <measurement group_id="B3" value="18" lower_limit="12" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth</title>
        <description>Based on hospital delivery records</description>
        <time_frame>At delivery</time_frame>
        <population>Complete randomized cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth</title>
          <description>Based on hospital delivery records</description>
          <population>Complete randomized cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1185"/>
                    <count group_id="O2" value="1185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404"/>
                    <measurement group_id="O2" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="831"/>
                    <count group_id="O2" value="827"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Live birth will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Live birth will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Semen Volume</title>
        <description>Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
        <time_frame>6 months</time_frame>
        <population>Analyzed overall and by fertility treatment stratum (subgroup) 870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Volume</title>
          <description>Volume of the ejaculate, mL Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
          <population>Analyzed overall and by fertility treatment stratum (subgroup) 870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="836"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.7"/>
                    <measurement group_id="O2" value="3.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.5"/>
                    <measurement group_id="O2" value="3.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.7"/>
                    <measurement group_id="O2" value="3.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.7"/>
                    <measurement group_id="O2" value="3.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Semen volume will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Semen volume will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sperm Concentration</title>
        <description>Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
        <time_frame>6 months</time_frame>
        <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, one male participant in the placebo arm had insufficient quantity or quality to assess concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Concentration</title>
          <description>Number of spermatozoa per unit of volume of semen Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
          <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, one male participant in the placebo arm had insufficient quantity or quality to assess concentration.</population>
          <units>10^6 spermatozoa/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="85.2"/>
                    <measurement group_id="O2" value="89.0" spread="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="96.5"/>
                    <measurement group_id="O2" value="76.1" spread="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="83.1"/>
                    <measurement group_id="O2" value="92.2" spread="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread="83.0"/>
                    <measurement group_id="O2" value="87.7" spread="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm concentration represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm concentration represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.2</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for fertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sperm Motility</title>
        <description>% motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
        <time_frame>6 months</time_frame>
        <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, one male participant in the placebo arm had insufficient quantity or quality to assess motility.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Motility</title>
          <description>% motile (including percentage of progressive motile sperm and percentage of nonprogressive motile sperm) Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
          <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, one male participant in the placebo arm had insufficient quantity or quality to assess motility.</population>
          <units>% motile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="794"/>
                    <count group_id="O2" value="835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="21.2"/>
                    <measurement group_id="O2" value="53.2" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="21.9"/>
                    <measurement group_id="O2" value="51.7" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="21.1"/>
                    <measurement group_id="O2" value="53.9" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="20.9"/>
                    <measurement group_id="O2" value="51.5" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm motility represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm motility represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sperm Morphology</title>
        <description>% normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
        <time_frame>6 months</time_frame>
        <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 19 men in the active arm and 17 men in the placebo arm had insufficient quantity or quality to assess morphology.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Morphology</title>
          <description>% normal morphology Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
          <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 19 men in the active arm and 17 men in the placebo arm had insufficient quantity or quality to assess morphology.</population>
          <units>% normal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="775"/>
                <count group_id="O2" value="819"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="775"/>
                    <count group_id="O2" value="819"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4.2"/>
                    <measurement group_id="O2" value="6.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="4.3"/>
                    <measurement group_id="O2" value="5.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="4.0"/>
                    <measurement group_id="O2" value="6.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="4.9"/>
                    <measurement group_id="O2" value="5.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm morphology represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. The confidence interval for sperm morphology represents 95.1% coverage to properly account for the alpha spent in the interim analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DNA Fragmentation Index</title>
        <description>Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
        <time_frame>6 months</time_frame>
        <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 44 men in the active arm and 55 men in the placebo arm had insufficient quantity or quality to assess DFI.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>DNA Fragmentation Index</title>
          <description>Comet assay used to measure sperm DNA integrity based on excess DNA strand breaks Assessed utilizing the World Health Organization (WHO) semen analysis procedure 5th edition World Health Organization. WHO laboratory manual for the Examination and processing of human semen. 5th Edition ed. Switzerland: 2010.</description>
          <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 44 men in the active arm and 55 men in the placebo arm had insufficient quantity or quality to assess DFI.</population>
          <units>% breakage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="750"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="750"/>
                    <count group_id="O2" value="781"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="20.5"/>
                    <measurement group_id="O2" value="27.2" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="19.6"/>
                    <measurement group_id="O2" value="26.8" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="20.3"/>
                    <measurement group_id="O2" value="27.0" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="22.7"/>
                    <measurement group_id="O2" value="28.5" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. DNA fragmentation will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. DNA fragmentation will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Motile Sperm Count</title>
        <description>Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile)</description>
        <time_frame>6 months</time_frame>
        <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 1 man in the active arm and 2 men in the placebo arm had insufficient quantity or quality to assess total motile count.</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Motile Sperm Count</title>
          <description>Calculated as semen volume (mL) * sperm concentration (10^6 spermatozoa/mL) * motility (% motile)</description>
          <population>870 and 903 men in the active and placebo treatment arms, respectively, returned for the 6-month study visit. 76 men in the active arm and 67 men in the placebo arm did not provide semen samples at this visit. Additionally, 1 man in the active arm and 2 men in the placebo arm had insufficient quantity or quality to assess total motile count.</population>
          <units>million motile sperm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
                <count group_id="O2" value="834"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="793"/>
                    <count group_id="O2" value="834"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" spread="226"/>
                    <measurement group_id="O2" value="182" spread="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVF stratum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" spread="221"/>
                    <measurement group_id="O2" value="152" spread="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment onsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="566"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" spread="226"/>
                    <measurement group_id="O2" value="188" spread="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other treatment offsite</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" spread="233"/>
                    <measurement group_id="O2" value="184" spread="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Total motile sperm count will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.7</ci_lower_limit>
            <ci_upper_limit>22.5</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Total motile sperm count will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.9</ci_lower_limit>
            <ci_upper_limit>21.4</ci_upper_limit>
            <estimate_desc>Weighted for loss to follow-up and adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation)</title>
        <description>A quantitative hCG evaluation in serum &gt; 5 milli-international units per milliliter (mIU/ml)</description>
        <time_frame>For IVF, 12 days post embryo transfer for day 5 embryo transfers, and 14 days post embryo transfer for day 3 embryo transfers; for couples undergoing OI/IUI, after self-report of positive pregnancy test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Human Chorionic Gonadotropin (hCG) Detected Pregnancy (Implantation)</title>
          <description>A quantitative hCG evaluation in serum &gt; 5 milli-international units per milliliter (mIU/ml)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479"/>
                    <measurement group_id="O2" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. hCG detected pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. hCG detected pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Intrauterine Pregnancy</title>
        <description>Visualized gestational sac in the uterus on ultrasound</description>
        <time_frame>approximately 6.5 weeks gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Intrauterine Pregnancy</title>
          <description>Visualized gestational sac in the uterus on ultrasound</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449"/>
                    <measurement group_id="O2" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Clinical intrauterine pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Clinical intrauterine pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ectopic Pregnancy</title>
        <description>Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound.</description>
        <time_frame>approximately 6.5 weeks gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ectopic Pregnancy</title>
          <description>Either visualization of no gestational sac in the uterus with a suspicious mass in the adnexa on ultrasound, an hCG level more than 1500 mIU/ml without visualization of an intrauterine gestational sac on ultrasound, or a slowly rising or plateauing serum hCG level without visualization of an intrauterine gestation on ultrasound.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Ectopic pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Ectopic pregnancy will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
            <estimate_desc>Adjusted for fertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Pregnancy Loss</title>
        <description>hCG pregnancy loss will be defined as a serum hCG &gt; 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation.</description>
        <time_frame>hcG-detected pregnancy until 20 weeks of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Early Pregnancy Loss</title>
          <description>hCG pregnancy loss will be defined as a serum hCG &gt; 5 mIU/ml followed by a decline. Clinically recognized pregnancy losses will be defined as visualization of an intrauterine gestational sac followed by a loss prior to 20 weeks gestation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Early pregnancy loss will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Early pregnancy loss will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preeclampsia or Gestational Hypertension</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Preeclampsia or Gestational Hypertension</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Preeclampsia/gestational hypertension will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Preeclampsia/gestational hypertension will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Diabetes</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Diabetes</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Gestational diabetes will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Gestational diabetes will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cesarean Delivery</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cesarean Delivery</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Cesarean delivery will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Cesarean delivery will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Delivery</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Delivery</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Preterm delivery will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Preterm delivery will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small for Gestational Age</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Small for Gestational Age</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Small for gestational age will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Small for gestational age will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <population>Among participants with live birth</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age</title>
          <description>Abstracted from hospital records and medical charts</description>
          <population>Among participants with live birth</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="2.5"/>
                    <measurement group_id="O2" value="38.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Gestational age will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <population>Among participants with live birth</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight</title>
          <description>Abstracted from hospital records and medical charts</description>
          <population>Among participants with live birth</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3062" spread="731"/>
                    <measurement group_id="O2" value="3133" spread="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Birth weight will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-64.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-156</ci_lower_limit>
            <ci_upper_limit>26.4</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stillbirth</title>
        <description>Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction.</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Stillbirth</title>
          <description>Loss at or after 20 weeks gestation. Determined based on hospital records and medical chart abstraction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Stillbirth will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Stillbirth will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Mortality</title>
        <description>Abstracted from hospital records and medical charts</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Mortality</title>
          <description>Abstracted from hospital records and medical charts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Neonatal mortality will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Neonatal mortality will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>8.95</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Neonatal Complications</title>
        <description>Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Major Neonatal Complications</title>
          <description>Abstracted from hospital records and medical charts: includes bronchopulmonary dysplasia, necrotizing enterocolitis, severe intraventricular hemorrhage, periventricular leukomalacia, and retinopathy of prematurity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Major neonatal complications will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Major neonatal complications will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>21.9</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Structural Malformations</title>
        <description>Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Structural Malformations</title>
          <description>Abstracted from birth record: includes major (n = 21; 6 with known genetic cause), minor (n = 6), and unclassified (n = 2) defects Structural birth defects: includes hydronephrosis/ureteropelvic junction obstruction, transposition of the great arteries, renal agenesis, cleft lip, club feet, multicystic/dysplastic kidney, tetralogy of fallot, gastroschisis, atrioventricular septal defects, other oral-facial defects, other cardiovascular defects, other CNS defects, other eye defects, other oral-facial defects, other anomalies, other syndromes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Structural malformations will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Structural malformations will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Maternal Morbidity</title>
        <description>Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Maternal Morbidity</title>
          <description>Abstracted from delivery record: including postpartum hemorrhage, anemia requiring transfusion, sepsis, seizure, HELLP syndrome or preeclampsia with pulmonary edema</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Severe maternal morbidity will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Severe maternal morbidity will be compared using two sided tests conducted at the 0.05 level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
            <estimate_desc>Adjusted for infertility treatment stratum and study site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilization Rate Per Cycle, %</title>
        <description>Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Fertilization rate unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilization Rate Per Cycle, %</title>
          <description>Among participants in the IVF stratum Oocytes will be assessed 16-18 hours after insemination or microinjection to determine whether fertilization occurred. Fertilization will be considered normal if two pronuclei and two polar bodies are identified. Oocytes without visible pronuclei will be considered unfertilized. Oocytes with more than two pronuclei will be considered abnormally fertilized, and will thus be discarded.</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Fertilization rate unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively</population>
          <units>percent per cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="2.25"/>
                    <measurement group_id="O2" value="77.7" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Fertilization rate will be compared using generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.90</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Good Quality Embryos on Day 5 Per Cycle</title>
        <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Day 5 good quality embryos unavailable in medical records for 56 and 64 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Good Quality Embryos on Day 5 Per Cycle</title>
          <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Day 5 good quality embryos unavailable in medical records for 56 and 64 participants in the active and placebo arms, respectively</population>
          <units>embryos per cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.23"/>
                    <measurement group_id="O2" value="2.98" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of good quality embryos will be compared using Poisson regression with generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Good Quality Embryos on Day 5 Per Cycle</title>
        <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Good Quality Embryos on Day 5 Per Cycle</title>
          <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 17 and 28 participants in the active and placebo arms, respectively</population>
          <units>percent per cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="2.05"/>
                    <measurement group_id="O2" value="18.5" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Proportion of good quality embryos on day 5 will be compared using generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.66</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Embryos Transferred Per Cycle</title>
        <description>Among participants in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 7 and 9 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Embryos Transferred Per Cycle</title>
          <description>Among participants in the IVF stratum</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Proportion day 5 good quality embryos unavailable in medical records for 7 and 9 participants in the active and placebo arms, respectively</population>
          <units>embryos per cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.06"/>
                    <measurement group_id="O2" value="1.51" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of embryos transferred will be compared using Poisson regression with generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Embryos Cryopreserved Per Cycle</title>
        <description>Among participants in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Number of embryos cryopreserved unavailable in medical records for 40 and 35 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Embryos Cryopreserved Per Cycle</title>
          <description>Among participants in the IVF stratum</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Number of embryos cryopreserved unavailable in medical records for 40 and 35 participants in the active and placebo arms, respectively</population>
          <units>embryos per cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="0.32"/>
                    <measurement group_id="O2" value="4.32" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of embryos cryopreserved will be compared using Poisson regression with generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sperm Penetration Per Cycle, %</title>
        <description>Among participants in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Sperm penetration &amp; unavailable in medical records for 114 and 121 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sperm Penetration Per Cycle, %</title>
          <description>Among participants in the IVF stratum</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Sperm penetration &amp; unavailable in medical records for 114 and 121 participants in the active and placebo arms, respectively</population>
          <units>percent penetration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="13.0"/>
                    <measurement group_id="O2" value="74.8" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Sperm penetration percentage will be compared using generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>21.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cells on Day 3 Per Embryo Per Cycle</title>
        <description>Among participants in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>1215 embryos among cycles among women in the FA/Zn arm; 1129 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 3 unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cells on Day 3 Per Embryo Per Cycle</title>
          <description>Among participants in the IVF stratum</description>
          <population>1215 embryos among cycles among women in the FA/Zn arm; 1129 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 3 unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively</population>
          <units>cells per embryo</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" spread="0.20"/>
                    <measurement group_id="O2" value="5.98" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of cells on day 3 will be compared with Poisson regression using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cells on Day 3 Per Embryo Per Cycle, Categorical</title>
        <description>Number of cells per embryo among women in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>1222 embryos among cycles among women in the FA/Zn arm; 1140 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 3 (categorical) unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cells on Day 3 Per Embryo Per Cycle, Categorical</title>
          <description>Number of cells per embryo among women in the IVF stratum</description>
          <population>1222 embryos among cycles among women in the FA/Zn arm; 1140 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 3 (categorical) unavailable in medical records for 25 and 36 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fewer than 4 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                    <measurement group_id="O2" value="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 cells or greater</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73"/>
                    <measurement group_id="O2" value="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of cells on day 3 will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>Fewer than 4 cells</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cells on Day 5 Per Embryo Per Cycle, Categorical</title>
        <description>Among participants in the IVF stratum</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>1160 embryos among cycles among women in the FA/Zn arm and 1205 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 5 (categorical) unavailable in medical records for 5 and 14 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cells on Day 5 Per Embryo Per Cycle, Categorical</title>
          <description>Among participants in the IVF stratum</description>
          <population>1160 embryos among cycles among women in the FA/Zn arm and 1205 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively&#xD;
# of cells on day 5 (categorical) unavailable in medical records for 5 and 14 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fewer than 8 cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20"/>
                    <measurement group_id="O2" value="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 cells or greater</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80"/>
                    <measurement group_id="O2" value="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Number of cells on day 5 will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Fewer than 8 cells</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Morphology on Day 3 Per Cycle, Categorical</title>
        <description>Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation.&#xD;
Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>961 embryos among cycles among women in the FA/Zn arm; 931 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 3 (categorical) unavailable in medical records for 27 and 37 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Morphology on Day 3 Per Cycle, Categorical</title>
          <description>Among participants in the IVF stratum Embryos will be scored three days after fertilization according to the size and shape of blastomeres and to their degree of fragmentation.&#xD;
Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74.:259-74.</description>
          <population>961 embryos among cycles among women in the FA/Zn arm; 931 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 3 (categorical) unavailable in medical records for 27 and 37 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent or good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66"/>
                    <measurement group_id="O2" value="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair or poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34"/>
                    <measurement group_id="O2" value="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Embryo morphology on day 3 will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Excellent or good morphology</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Morphology on Day 5 Per Cycle, Categorical</title>
        <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>973 embryos among cycles among women in the FA/Zn arm; 1009 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 5 (categorical) unavailable in medical records for 10 and 19 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Morphology on Day 5 Per Cycle, Categorical</title>
          <description>Among participants in the IVF stratum For couples who meet criteria for blastocyst culture, embryos will be graded 5 days after fertilization based on Society for Assisted Reproductive Technologies (SART) morphology criteria.</description>
          <population>973 embryos among cycles among women in the FA/Zn arm; 1009 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Embryo morphology on day 5 (categorical) unavailable in medical records for 10 and 19 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent or good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                    <measurement group_id="O2" value="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair or poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72"/>
                    <measurement group_id="O2" value="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Embryo morphology on day 5 will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Excellent or good morphology</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Method of Fertilization Per Cycle</title>
        <description>Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>1689 embryos among cycles among women in the active treatment arm; 1800 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Method of fertilization unavailable in medical records for 2 and 5 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Method of Fertilization Per Cycle</title>
          <description>Among participants in the in vitro fertilization (IVF) stratum: method of fertilization classified into intracytoplasmic sperm injection (ICSI) and other</description>
          <population>1689 embryos among cycles among women in the active treatment arm; 1800 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Method of fertilization unavailable in medical records for 2 and 5 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                    <measurement group_id="O2" value="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26"/>
                    <measurement group_id="O2" value="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Method of fertilization will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>ICSI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Embryos Transferred Per Cycle, Categorical</title>
        <description>Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>172 embryos among cycles among women in the FA/Zn arm; 187 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Quality of embryos transferred (categorical) unavailable in medical records for 21 and 30 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Embryos Transferred Per Cycle, Categorical</title>
          <description>Among participants in the IVF stratum Embryonic grading based on Society for Assisted Reproductive Technologies (SART) morphology criteria</description>
          <population>172 embryos among cycles among women in the FA/Zn arm; 187 embryos among cycles among women in the placebo arm 124 and 135 participants randomized to active and placebo arms, respectively Quality of embryos transferred (categorical) unavailable in medical records for 21 and 30 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent or good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                    <measurement group_id="O2" value="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair or poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Quality of embryos transferred will be compared using generalized estimating equations accounting for multiple embryos per cycle and multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Excellent or good quality</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chromosomal Complement of Embryo Per Cycle</title>
        <description>Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al.&#xD;
Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8.</description>
        <time_frame>Up to 9 months of fertility treatment post-randomization</time_frame>
        <population>124 and 135 participants randomized to active and placebo arms, respectively Chromosomal complement of embryo unavailable in medical records for 121 and 124 participants in the active and placebo arms, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Folic Acid and Zinc Supplementation</title>
            <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Chromosomal Complement of Embryo Per Cycle</title>
          <description>Among participants in the IVF stratum Chromosomal complement in the embryo assessed using methodology cited by Rubio et al.&#xD;
Rubio C, Rodrigo L, Mir P et al. Use of array comparative genomic hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril 2013 March 15;99(4):1044-8.</description>
          <population>124 and 135 participants randomized to active and placebo arms, respectively Chromosomal complement of embryo unavailable in medical records for 121 and 124 participants in the active and placebo arms, respectively</population>
          <units>predicted probability</units>
          <param>Number</param>
          <units_analyzed>cycles</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>cycles</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                    <measurement group_id="O2" value="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis plan is based on an &quot;intention-to-treat&quot; (ITT) approach comparing the two treatment arms based on the randomized assignment. The common null hypothesis states that the effect of folic acid/zinc on the outcomes is null compared to the placebo. Chromosomal complement will be compared using generalized estimating equations accounting for multiple cycles per couple.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>7.43</ci_upper_limit>
            <estimate_desc>Abnormal</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reproductive Hormones and Other Measured Biomarkers</title>
        <description>Urinary, serum, and salivary concentrations of reproductive hormones, particularly androgens, proteomic analysis of human sperm and cardiometabolic risk factors and markers of oxidative stress, as well as measures of trace elements in toenails (collected at month 4 clinic visit). Biospecimens have been collected but laboratory analysis still needs to be done to be able to evaluate these endpoints.</description>
        <time_frame>4 or 6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the 6 month duration of the study.</time_frame>
      <desc>Adverse events were only collected from the male partners.</desc>
      <group_list>
        <group group_id="E1">
          <title>Folic Acid and Zinc Supplementation</title>
          <description>5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.&#xD;
5 mg folic acid and 30 mg elemental zinc</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo, taken orally daily for 6 months.&#xD;
Placebo Comparator: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1185"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilic oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1185"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1185"/>
              </event>
              <event>
                <sub_title>Variococele repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort or pain</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1185"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Enrique Schisterman</name_or_title>
      <organization>NICHD</organization>
      <phone>3014356893</phone>
      <email>schistee@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

